Provided by Tiger Trade Technology Pte. Ltd.

Babson Capital Corporate Investors

17.61
-0.9000-4.86%
Post-market: 17.610.00000.00%16:10 EDT
Volume:94.65K
Turnover:1.69M
Market Cap:360.98M
PE:12.88
High:18.78
Open:18.54
Low:17.50
Close:18.51
52wk High:23.79
52wk Low:17.50
Shares:20.50M
Float Shares:- -
Volume Ratio:4.27
T/O Rate:- -
Dividend:1.60
Dividend Rate:9.08%
EPS(TTM):1.37
EPS(LYR):1.37
ROE:8.19%
ROA:4.57%
PB:1.06
PE(LYR):12.88

Loading ...

Press Release: Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Dow Jones
·
Mar 26

Barings Corporate Investors announces annual shareholder meeting

Reuters
·
Mar 26

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

GlobeNewswire
·
Mar 21

Noreen Clifford, Chairman of Fund, disposed of USD 188,000 in Barings Corporate Investors common shares

Reuters
·
Mar 19

Barings Corporate Investors Publishes 2025 Annual Report

Reuters
·
Mar 01

Barings Corporate Investors Q4 net unrealized appreciation at USD 986,805.0 million after Q3 net unrealized depreciation of USD 419,454.0 million

Reuters
·
Feb 27

Barings Corporate Investors Q4 Dividend USD 0.4

THOMSON REUTERS
·
Feb 27

Press Release: Barings Corporate Investors Reports Preliminary Fourth Quarter 2025 Results

Dow Jones
·
Feb 27

Barings Corporate Investors announces $0.40 per share quarterly dividend

Reuters
·
Dec 12, 2025

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

GlobeNewswire
·
Dec 04, 2025

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

GlobeNewswire
·
Dec 03, 2025

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

GlobeNewswire
·
Nov 28, 2025

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

GlobeNewswire
·
Nov 25, 2025

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

GlobeNewswire
·
Nov 14, 2025

Barings Corporate Investors reports Q3 net investment income of $7.1 million

Reuters
·
Nov 14, 2025

Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

GlobeNewswire
·
Nov 05, 2025

India Inflation Cools Further in September

MT Newswires Live
·
Oct 14, 2025

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

GlobeNewswire
·
Oct 14, 2025